Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. News
  7. Summary
    IVA   FR0013233012

INVENTIVA

(IVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inventiva announces participation at several investor conferences in November 2021

11/01/2021 | 09:49am EST

Daix (France), Long Island City (New York, United States) - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company's leadership will participate in two upcoming conferences in November 2021.

Contact:

Westwicke

ICR Company

Patricia L.

Bank Relations

E: patti.bank@westwicke.com

T: +1 415 513-1284

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about INVENTIVA
01/14INVENTIVA : to present at the 40th Annual J.P. Morgan Healthcare Conference
PU
01/14Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
AQ
01/06INVENTIVA : Corporate Presentation January 2021
PU
2021INVENTIVA : Monthly statement on outstanding equity shares and voting rights
CO
2021Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021Inventiva Confirms Safety of Liver Disease Drug in Clinical Trial Measuring Cardiac Ele..
MT
2021INVENTIVA : announces positive results of clinical thorough QT study conducted with lanifi..
PU
2021Inventiva announces positive results of clinical thorough QT study conducted with lanif..
AQ
2021Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanif..
CI
2021INVENTIVA : Corporate Presentation December 2021
PU
More news
Analyst Recommendations on INVENTIVA
More recommendations
Financials
Sales 2021 5,07 M 5,74 M 5,74 M
Net income 2021 -51,6 M -58,5 M -58,5 M
Net cash 2021 47,3 M 53,6 M 53,6 M
P/E ratio 2021 -9,12x
Yield 2021 -
Capitalization 449 M 509 M 509 M
EV / Sales 2021 79,4x
EV / Sales 2022 10,9x
Nbr of Employees 100
Free-Float 78,3%
Chart INVENTIVA
Duration : Period :
Inventiva Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 11,00 €
Average target price 27,23 €
Spread / Average Target 148%
EPS Revisions
Managers and Directors
FrÚdÚric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Michael P. Cooreman Chief Medical Officer
Alice Roudot-Ketelers Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
INVENTIVA-6.30%509
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-0.66%52 665
BIONTECH SE-23.97%47 338